TETSUO ASHIZAWA to Treatment Outcome
This is a "connection" page, showing publications TETSUO ASHIZAWA has written about Treatment Outcome.
Connection Strength
0.059
-
Antisense oligonucleotide targeting DMPK in patients with myotonic dystrophy type 1: a multicentre, randomised, dose-escalation, placebo-controlled, phase 1/2a trial. Lancet Neurol. 2023 03; 22(3):218-228.
Score: 0.016
-
Towards development of a statistical framework to evaluate myotonic dystrophy type 1 mRNA biomarkers in the context of a clinical trial. PLoS One. 2020; 15(4):e0231000.
Score: 0.013
-
Rare neurological channelopathies--networks to study patients, pathogenesis and treatment. Nat Rev Neurol. 2016 Apr; 12(4):195-203.
Score: 0.010
-
Emerging therapies in Friedreich's ataxia. Neurodegener Dis Manag. 2016; 6(1):49-65.
Score: 0.010
-
Coenzyme Q10 and spinocerebellar ataxias. Mov Disord. 2015 Feb; 30(2):214-20.
Score: 0.009